Bright Green Partners with Benuvia Pharmaceuticals for Supply
![Bright Green Partners with Benuvia Pharmaceuticals for Supply](https://investorshangout.com/images/blog/investors-hangout-newswire.jpg)
Bright Green Partners with Benuvia Pharmaceuticals
Bright Green Corporation (NASDAQ: BGXX) announced that it has signed a letter of intent to supply its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a leader in pharmaceutical cannabinoids, as well as psychedelic molecules currently under investigation for clinical use.
Strategic Supply Agreement
This agreement signals Bright Green’s commitment to supply US pharmaceutical partners with high-quality organic materials. Benuvia intends to leverage Bright Green’s unique position to produce Schedule I & II raw materials in compliance with Good Agricultural and Collection Practices (GACP), Good Manufacturing Practices (GMP), and the DEA, all within the USA.
Advancing Pharmaceutical Development
Bright Green aims to become the leading domestic supplier of DEA-controlled, plant-based raw materials for cannabinoid, psychedelic, and opioid-based drugs. With ongoing fundraising and supply agreements, Bright Green is well-positioned for a strong performance.
Compliance and Standards
The Drug Enforcement Administration (DEA) has completed its annual operational procedures for Schedule I & II drug cultivation and manufacturing. Bright Green meets these high national standards and is closer to beginning operations to supply the pharmaceutical industry with necessary materials.
About Bright Green Corporation
Bright Green is one of the few companies authorized to grow, manufacture, and sell Schedule I and II plant-based drugs legally under federal and state law. Bright Green’s approval from the DEA enables it to advance its vision of improving quality of life through cannabis and other plant-based therapies.
About Benuvia
Benuvia Operations, LLC is a leader in the research, development, and commercialization of innovative pharmaceutical products. Committed to improving patient outcomes through scientific study and quality practices, Benuvia operates at the forefront of the pharmaceutical industry.
Media Inquiries & Investor Relations
For media inquiries and investor relations, please contact ir@brightgreen.us.
Frequently Asked Questions
What is the nature of the partnership between Bright Green and Benuvia?
The partnership involves Bright Green supplying DEA-approved marijuana extracts and plant-based psychedelics to Benuvia for pharmaceutical use.
What are the regulatory approvals held by Bright Green?
Bright Green holds authorization from the US government and the New Mexico Board of Pharmacy to legally grow, manufacture, and sell Schedule I and II plant-based drugs.
What standards does Bright Green comply with?
Bright Green complies with Good Agricultural and Collection Practices (GACP) and Good Manufacturing Practices (GMP).
What is Benuvia known for?
Benuvia is recognized for its FDA-approved medication SYNDROS, used for treating anorexia associated with weight loss in patients with AIDS and managing chemotherapy-induced nausea and vomiting.
How does this partnership affect the pharmaceutical market?
This partnership is expected to enhance the supply of high-quality raw materials in the pharmaceutical market, particularly for cannabinoid and psychedelic products.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/